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Understanding of prognosis in non-metastatic prostate cancer:
a randomised comparative study of clinician estimates
measured against the PREDICT prostate prognostic model
David R. Thurtle1, Valerie Jenkins 2, Paul D. Pharoah3 and Vincent J. Gnanapragasam1
PREDICT Prostate is an individualised prognostic model that provides long-term survival estimates for men diagnosed with non-
metastatic prostate cancer (www.prostate.predict.nhs.uk). In this study clinician estimates of survival were compared against model
predictions and its potential value as a clinical tool was assessed. Prostate cancer (PCa) specialists were invited to participate in the
study. 190 clinicians (63% urologists, 17% oncologists, 20% other) were randomised into two groups and shown 12 clinical
vignettes through an online portal. Each group viewed opposing vignettes with clinical information alone, or alongside PREDICT
Prostate estimates. 15-year clinician survival estimates were compared against model predictions and reported treatment
recommendations with and without seeing PREDICT estimates were compared. 155 respondents (81.6%) reported counselling new
PCa patients at least weekly. Clinician estimates of PCa-speciﬁc mortality exceeded PREDICT estimates in 10/12 vignettes. Their
estimates for treatment survival beneﬁt at 15 years were over-optimistic in every vignette, with mean clinician estimates more than
5-fold higher than PREDICT Prostate estimates. Concomitantly seeing PREDICT Prostate estimates led to signiﬁcantly lower reported
likelihoods of recommending radical treatment in 7/12 (58%) vignettes, particularly in older patients. These data suggest clinicians
overestimate cancer-related mortality and radical treatment beneﬁt. Using an individualised prognostic tool may help reduce
overtreatment.
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BACKGROUND
Decision-making around treatment for non-metastatic prostate
cancer (PCa) is notoriously complex. Shared decision-making
depends upon both clinician and patient having a good under-
standing of the beneﬁts and harms of different management
options. Estimation of life expectancy is known to be poor among
PCa specialists.1,2 However, it is currently unknown how well
clinicians estimate mortality risk from prostate cancer, nor how
these perceptions affect treatment recommendations.
PREDICT Prostate is a new individualised prognostic model and
decision aid developed and validated within cohorts of over
12,000 PCa patients.3 The model provides unbiased and persona-
lised 15-year cancer-speciﬁc and overall survival estimates, along-
side estimates of survival beneﬁt from radical therapy compared
with conservative management. Its accuracy is demonstrated by
concordance indices in the region of 0.84 and the model has
recently been successfully retested in an external validation cohort
of over 69,000.4 PREDICT Prostate (www.prostate.predict.nhs.uk)
can thus inform decisions with a quantiﬁable reference for
prognosis. It has also recently been endorsed by the National
Institute for Health and Care Excellence (NICE). In this study, we
used this model as a standardised reference to compare against
clinician estimates of prognosis and assessed its potential impact
on treatment recommendations.
METHODS
A randomised online virtual clinic was developed using Qualtrics®
research software (Utah, USA). Prostate cancer specialists were
invited to participate predominantly through professional mailing
lists between June and September 2018. Respondents were
encouraged to share the survey link with local colleagues. No
incentive was offered for participation. Participants were rando-
mised into two groups and shown 12 clinical vignettes of men
with PCa: ﬁrst 6 vignettes with clinical information alone, and then
6 vignettes with clinical information alongside PREDICT Prostate
survival estimates. Each group saw the opposite 6 vignettes with
and without the PREDICT estimates. Survey progression was uni-
directional—preventing respondents from amending previous
answers. Clinician estimates of 15-year survival outcomes were
compared to PREDICT Prostate estimates. The likelihoods of
recommending treatment were compared between the randomi-
sation groups. Each case vignette was designed to represent
scenarios in which use of the PREDICT Prostate tool might be
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appropriate (Fig. 1). The full questionnaires are available in
Supplementary Information 1. Data analyses were performed
using Stata 14 (Texas, USA). Responses were anonymised.
RESULTS
190 responses were received from 121 urologists (64% [85
consultants, 36 trainees]), 32 oncologists (17% [29 consultants, 3
trainees), 25 PCa specialist nurses (13.2%) and 12 other profes-
sionals (6%); henceforth collectively referred to as ‘clinicians’. Sixty
percent of respondents reported working in specialist cancer
centres and 82% reported counselling men with PCa at least
weekly. 81% and 19% of respondents reported working in a UK, or
non-UK centre, respectively. Clinician estimates of 15-year PCSM
varied signiﬁcantly and exceeded PREDICT Prostate estimates in
most cases (83%) (Fig. 1). Mean clinician estimates of PCSM across
all 12 cases were 1.9-fold greater than PREDICT Prostate estimates.
Perceptions of survival beneﬁt from upfront radical treatment at
15 years were similarly much higher, with mean clinician estimates
of survival beneﬁt 5.4-fold greater than the matched PREDICT
Prostate estimates (Supplementary Table 1).
Likelihood of recommending treatment using clinical informa-
tion alone correlated with clinician estimates of PCSM and with
traditional three-stratum risk stratiﬁcation criteria (Supplementary
Table 1). It was also strongly inﬂuenced by patient age, with
treatment recommendations particularly high (>80%) in younger
men (<65years) with any ‘high risk’ features.5
Concomitantly viewing estimates from PREDICT Prostate led to
reductions in likelihood of recommending radical treatment in 11/
12 (92%) vignettes (Fig. 2), with signiﬁcant differences (p < 0.05) in
7/12 (58%). Percentage decreases were most evident in inter-
mediate risk cases, older patients (>70 years) and in the presence
of comorbidity. For example, in a 75-year old man with PSA 5.1 and
Gleason 3+4 disease in 2/12 biopsy cores (Case B1), the mean
likelihood of recommending treatment fell from 32.5% with clinical
information alone to 19.1% when PREDICT estimates were also
shown (p= 0.009). Although reported likelihood of recommending
treatment differed substantially between the two groups, the vast
majority of respondents felt the PREDICT Prostate estimates were
‘similar to’ what they expected (Supplementary Fig. 1). Overall, 81%
of respondents felt PREDICT Prostate would be a useful clinical tool.
DISCUSSION
Clinician understanding of PCa prognosis in non-metastatic
disease is not well-explored in the literature. However, estimates
of overall life expectancy in patients with PCa among urologists,
oncologists and other health professionals are known to suffer
from ‘inaccuracy, imprecision and inconsistency’.1,2 Our study
suggests that PCa professionals generally overestimate cancer-
related mortality. The results also suggest that clinicians’ percep-
tions of treatment effectiveness are generally over-optimistic; well
in excess of a 75% improvement which does not correlate with
direct evidence from RCTs.6,7
Our ﬁndings, that clinicians recommend radical treatment in
most intermediate or high risk PCa, are unsurprising with the
current reliance on a three-tier risk-stratiﬁcation system. However,
growing evidence supports the judicious use of surveillance in
some men with intermediate-risk disease, and more individualised
approaches are being sought.8 Overtreatment even of low-risk
disease also remains a signiﬁcant issue in PCa management, with
up to 24% being managed with radical therapy in some centres in
the UK.9 Our results suggest that by providing individualised and
contextualised prognostic information, PREDICT Prostate may
prompt clinicians to re-evaluate prognosis estimation and increase
consideration of non-interventional strategies. This may be
particularly true for older patients, or those with comorbidities,
where the modelled overall survival beneﬁts from treatment in
Case A1: 64years, PSA 23, GG4, T3, 3/12bx, CCI = 0
0 10 20 30 40 50 60 70 80 90 100
Case A2: 72years, PSA 8.2, GG1, T2, 3/14bx, CCI = 1
Case A3: 54years, PSA 14.0, GG3, T2, 2/12bx, CCI = 0
Case A4: 68years, PSA 13.4, GG3, T2, 8/16bx, CCI = 0
Case A5: 60years, PSA 6.4, GG2, T1, 2/12Bx, CCI = 0
Case A6: 83years, PSA 24, GG2, T1, 1/12Bx, CCI = 1
Case B1: 75years, PSA 5.1, GG2, T1, 2/12bx, CCI = 0
Case B2: 57years, PSA 12, GG3, T2, 10/12bx, CCI = 0
Case B3: 71years, PSA 9.0, GG1, T2, 3/12bx, CCI = 0
Case B4: 58years, PSA 15.3, GG3, T2, 7/14bx, CCI = 0
Case B5: 61years, PSA 6.1, GG2, T3, 2/12bx, CCI = 0
Case B6: 81years, PSA 6.1, GG2, T1, 1/12Bx, CCI = 1
Fig. 1 Boxplots showing the median, IQR and range of clinician estimated percentages of men dying of prostate cancer by 15 years after
diagnosis without radical treatment for each of 12 case vignettes. For comparison, the PREDICT Prostate estimates for prostate cancer death by
15 years are shown by blue diamonds. PSA prostate-speciﬁc antigen, T clinical tumour stage, GG grade group, bx biopsy cores, CCI Charlson
Comorbidity Index
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PREDICT are adjusted for competing risks, rather than relying
upon cancer-speciﬁc survival alone.
This study has many strengths as it represents the reported
behaviour of a diverse spectrum of prostate cancer professionals
within a randomised design and where the pre-deﬁned sample
size was exceeded. However, we recognise the study limitations
inherent to questionnaire-based research. These ﬁndings were
from a predominantly UK context and stated change in
recommendations may not equal actual change in practice. The
reported profession of respondents cannot be conﬁrmed, and the
ﬁnal response rate cannot be determined due to the method of
recruitment. Some respondents, may rarely manage patients with
the localised prostate cancer characteristics described in the
vignettes, however, all would be expected to partake in prostate
cancer multi-disciplinary team (MDT) meetings. The survival
endpoint of 15 years may also be unfamiliar, and we fully
acknowledge that clinicians may recommend a therapy, but ﬁnal
treatment decisions are made by the patient himself. Nonetheless,
physician recommendations do remain very important in guiding
patients’ decisions.10 A randomised impact study of the PREDICT
Prostate tool with patients is currently underway and a wider study
to measure the actual change in treatment uptake is being
planned.
In summary, this study suggests that PCa specialists appear to
overestimate PCa-related mortality and the survival beneﬁts of
radical treatment for non-metastatic PCa. Using a freely available
tool such as PREDICT Prostate can provide individualised and
contextualised prognostic information which standardises the
information patients receive. This may then help reduce variability
in recommendations and facilitate unbiased and better-informed
clinician-patient discussions. In turn, this may aid the reduction of
overtreatment of good prognosis disease while also increasing the
conﬁdence that radical treatment, when needed, will confer a
survival beneﬁt and justify the risks of side effects. At the very
basic level, it should enhance patient’s knowledge of risks and
beneﬁts and their ability to participate in their care.
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Fig. 2 Mean difference in clinician likelihood of recommending radical treatment when shown PREDICT Prostate estimates in addition to
routine diagnostic clinical information alone. Results for all 12 hypothetical cases are shown, sorted by EAU risk group. The case number, age
and Charlson comorbidity index (CCI) is reported. Further case details are shown in Fig. 1 and Supplementary Information 1
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